News
BLRX
0.3234
-40.68%
-0.2218
Amended: BioLineRx Inks License Agreement With Ayrmid To Commercialize Aphexda
NASDAQ · 12h ago
BioLineRx inks licensing deal, share purchase agreement
Seeking Alpha · 13h ago
BiolineRx Ltd. Announces New Direct Offering of Shares
TipRanks · 13h ago
BioLineRx Signs A $10mln Upfront Deal With Ayrmid To Commercialise APHEXDA
NASDAQ · 13h ago
BRIEF-BioLine Rx Files For Offering 4.1 Million ADSS To Certain Institutional Investors
Reuters · 14h ago
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell
TipRanks · 14h ago
BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial Milestones, Plus Royalties Between 18%-23% On Net Sales Of Aphexda
Benzinga · 14h ago
BRIEF-BioLineRx and Ayrmid Enter Exclusive License Agreement
Reuters · 14h ago
Weekly Report: what happened at BLRX last week (1111-1115)?
Weekly Report · 3d ago
BioLineRx Granted Extension to Meet Nasdaq Requirements
TipRanks · 11/12 21:56
Weekly Report: what happened at BLRX last week (1104-1108)?
Weekly Report · 11/11 10:21
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
Benzinga · 11/06 12:45
BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials
TipRanks · 11/05 14:29
BRIEF-Biolinerx Announces Oral Presentation On Data From Phase 1 Clinical Trial
Reuters · 11/05 14:11
BioLineRx Announces Oral Presentation On Data From Phase 1 Clinical Trial Evaluating Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapies In Sickle Cell Disease At ASH 2024
Benzinga · 11/05 14:08
Weekly Report: what happened at BLRX last week (1028-1101)?
Weekly Report · 11/04 10:21
Weekly Report: what happened at BLRX last week (1021-1025)?
Weekly Report · 10/28 10:15
Weekly Report: what happened at BLRX last week (1014-1018)?
Weekly Report · 10/21 10:14
BioLineRx receives USPTO allowance of new composition of matter patent on motixafortide
Seeking Alpha · 10/16 13:10
BioLineRx Secures Extended U.S. Patent for Motixafortide
TipRanks · 10/16 11:27
More
Webull provides a variety of real-time BLRX stock news. You can receive the latest news about Biolinerx through multiple platforms. This information may help you make smarter investment decisions.
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.